In a paper recently published in the Journal of Infectious Diseases, researchers examined the effect of vaginal tenofovir 1 percent gel use on the risk of acquiring herpes simplex virus type 2, or HSV-2. The study was conducted through a secondary analysis of data from the VOICE study, the primary results of which were published in 2015.
* This article was originally published here
